BioCardia Advances Promising Cell Therapy Trials for Cardiovascular Conditions with Encouraging Results and Japanese Approval in Sight
SUNNYVALE, Calif. Dec. 19, 2023 - BioCardia, Inc. Nasdaq: BCDA, a leading developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, continues to make significant progress in its clinical trials for the treatment of various cardiovascular conditions. The company recently announced the completion of enrollment in its groundbreaking CardiAMP Cell Therapy trial for the treatment of chronic myocardial ischemia, alongside dosing the first patient in its CardiALLO trial for ischemic heart failure. Additionally, BioCardia received positive support from the Japan Pharmaceutical and Medical Device Agency (PMDA), indicating the potential approval of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) in Japan.
The completion of enrollment in the CardiAMP Cell Therapy trial marks a significant milestone for BioCardia and its breakthrough treatment for chronic myocardial ischemia. This open-label roll-in cohort trial will pave the way for the pivotal randomized trial and is set to reveal highly anticipated results. To discuss the outcomes and delve into the details of the pivotal randomized trial, a call with the study’s clinical leadership has been scheduled.
In tandem with this achievement, BioCardia administered its first treatment in the CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial. This trial aims to treat patients with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction (HFrEF) using BCDA-03 allogeneic mesenchymal stem cells. With this trial, BioCardia seeks to further expand its therapeutic options for patients suffering from ischemic heart failure, potentially revolutionizing the field of regenerative medicine.
The positive consultation minutes received from the Japan Pharmaceutical and Medical Device Agency (PMDA) regarding the CardiAMP Heart Failure Trial (CardiAMP HF) offer great optimism for BioCardia’s future in the Japanese market. The consultation minutes support the belief that the CardiAMP autologous cell therapy may receive approval for the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) based on follow-up data from the patients currently enrolled in the CardiAMP HF trial. Pending the availability of this data in Q4 2024, the approval could significantly impact the lives of Japanese patients suffering from this debilitating condition.
BioCardia’s commitment to advancing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases reinforces its position as a leader in the field. With the progress made in the CardiAMP and CardiALLO trials, coupled with the potential approval in Japan, BioCardia is bringing hope to patients around the world. The company’s groundbreaking work showcases the tremendous potential of cell therapy in treating cardiovascular conditions, presenting a brighter future for those affected by heart failure and ischemic heart disease.
Comments